Germán Seara, Co-Director of the Innovation Unit of the San Carlos Clinical Hospital, participated last Saturday, February 8, in the second training module launched by EUPATI-Spain to train patients and representatives of patient organizations in “Technology Assessment sanitary “.
In his paper “The evidence of the patient: Research tools and analysis of the voice of the patient” showed the evolution of the concept of “evidence” as proofs that determines the reality of the processes, how “it” is applied in the field of healthcare and how it relates to the aspects that have to do with the individual clinical experience of the professionals and the values and expectations of the patients.
The objective of the training module is to provide patients and their representatives with the competencies and skills in the field of decision making in research, in clinical trials and in regulatory processes, at a time when more and more, Organizations and administrations are looking to involve patients in decision making as a method of process improvement.
In the training module participated:
• Juan Estévez, of the Spanish Agency for Medicines and Health Products (AEMPS), • Arantxa Romero, of the National Network of Health Technology Assessment Agencies and benefits of the National Health System (REDETS) and Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) • Lilisbeth Perestelo, from the National Network of Health Technology Assessment Agencies and benefits of the National Health System (REDETS) and Evaluation and Planning Service of the Canary Health Service (SESCS) • Carina Escobar, President of the Patient Organizations Platform (POP) • Francisco J. Fernández, communication director of Farmaindustria. • Germán Seara, Co Director of the Innovation Unit of the San Carlos Clinical Hospital.
EUPATI is a network of European national platforms. The European Patient Academy (EUPATI) is a pan-European project of the Innovative Medicines Initiative involving 33 organizations, led by the European Patients Forum and with patient organization partners (European Genetic Alliance, European AIDS Treatment Group and EURORDIS ), universities and non-profit organizations in addition to a number of pharmaceutical companies.